Adults older than 45 and children younger than 18 years
Platelet count higher than 30x109/l at time of screening
Suspicion of secondary ITP
Positive family history for ITP
Presence or history of autoimmune disease as judged by the investigator
Hepatosplenomegaly
Presence or history of relevant hepatic disease as judged by the investigator
Presence or history of thromboembolic disease as judged by the investigator
Patients with splenectomy
Women who are pregnant or breast feeding
Intention to become pregnant during the course of the study
Lack of safe double contraception (see 7.1)
Any vaccination 2 weeks prior start of the study
Drugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center
Known or suspected non-compliance, drug or alcohol abuse
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia of the study subject
Participation in another study with investigational drug within the 30 days preceding and during the present study
Previous enrolment into the current study
Previous treatment with romiplostim or eltrombopag
Hypersensitivity to the active substance or to any of the excipients or to E. coli derived proteins
Enrolment of the investigator, his/her family members, employees and other dependent persons

NCT02760251_exc_T1
Person
Adults
NCT02760251_exc_T2
Value
older than 45
NCT02760251_exc_T3
Person
children
NCT02760251_exc_T4
Value
younger than 18 years
NCT02760251_exc_T5
Measurement
Platelet count
NCT02760251_exc_T6
Value
higher than 30x109/l
NCT02760251_exc_T7
Temporal
at time of screening
NCT02760251_exc_T8
Reference_point
screening
NCT02760251_exc_T9
Condition
secondary ITP
NCT02760251_exc_T10
Observation
family history for ITP
NCT02760251_exc_T12
Condition
autoimmune disease
NCT02760251_exc_T17
Condition
hepatic disease
NCT02760251_exc_T18
Qualifier
relevant
NCT02760251_exc_T21
Condition
thromboembolic disease
NCT02760251_exc_T22
Procedure
splenectomy
NCT02760251_exc_T26
Procedure
vaccination
NCT02760251_exc_T27
Temporal
2 weeks prior start of the study
NCT02760251_exc_T28
Reference_point
start of the study
NCT02760251_exc_T30
Condition
alcohol abuse
NCT02760251_exc_T31
Condition
l ab y to
NCT02760251_exc_T32
Qualifier
non-compliance
NCT02760251_exc_T33
Scope
drug or alcohol abuse
NCT02760251_exc_T37
Drug
romiplostim
NCT02760251_exc_T38
Drug
eltrombopag
NCT02760251_exc_T39
Condition
Hypersensitivity
NCT02760251_exc_T42
Condition
Hepatosplenomegaly